Novel Combination Therapy Enhances Control of Advanced Prostate Cancer

Advancements in Prostate Cancer Treatment: A Closer Look at the ZZ-FIRST Study

In a significant breakthrough for the treatment of advanced hormone-sensitive prostate cancer, MEDSIR, a prominent international oncology research firm, presented compelling findings from its ZZ-FIRST study during the ASCO 2026 scientific congress held in Chicago. The study aims to enhance the treatment response for patients suffering from high-volume metastatic hormone-sensitive prostate cancer (mHSPC) through a combined therapeutic approach involving enzalutamide and talazoparib.

The ZZ-FIRST study involved a cohort of 54 patients from various centers across Spain, marking a critical step in empowering clinicians to better manage this aggressive cancer. Standard care for mHSPC typically involves androgen deprivation therapy, often supplemented with newer hormonal drugs like enzalutamide. However, the challenge lies in the unfortunate tendency for tumors to develop resistance to these treatments over time.

Recognizing this challenge, the ZZ-FIRST study aims to tackle the issue head-on by intensifying initial therapy. The innovative strategy combines enzalutamide – which disrupts androgen signaling – with talazoparib, a PARP inhibitor known for its role in DNA repair. By employing these two drugs concurrently while patients are still responsive to hormonal treatment, researchers hope to amplify the DNA damage in cancer cells, thwarting their ability to adapt and develop resistance.

Preliminary results from the study demonstrated that patients receiving this experimental combination achieved a remarkable radiographic progression-free survival rate of 45.3 months. This is a marked improvement over the 31.1 months observed in patients treated exclusively with enzalutamide. This measure is critical because it gauges the duration during which patients remain free from observable tumor progression through imaging exams.

Moreover, participants in the combination therapy group experienced extended timeframes before manifesting PSA progression and before developing resistance to hormonal treatments. These results underscore the potential benefits of coupling hormonal therapies with PARP inhibitors, especially for those patients whose tumors may have specific mutation profiles in DNA repair genes.

Dr. Joaquín Mateo, the principal investigator of the ZZ-FIRST study, emphasized the importance of delving into the biological underpinnings of tumor resistance to treatments. According to Dr. Mateo, "Understanding the mechanisms that allow tumors to develop resistance is vital. Exploring new strategies can significantly alter patient outcomes and delay disease progression."

Funding for the ZZ-FIRST study has come from esteemed sources including Pfizer S.L., the Spanish Association Against Cancer (AECC), and the United States Department of Defense (DoD). The medications utilized in the study were supplied by Pfizer S.L. (talazoparib) and Astellas Pharma Europe Ltd. (enzalutamide).

Broader Collaborative Efforts

Apart from the ZZ-FIRST findings, MEDSIR also presented additional research initiatives during the ASCO congress. In collaboration with the Menarini Group, the company unveiled the studies behind ADELA, an international phase III trial that tests the efficacy of combining the selective estrogen receptor degrader (SERD) elacestrant with everolimus in patients who have previously developed ESR1 gene mutations after undergoing standard endocrine therapies.

Simultaneously, the CADILLAC study, which is in progress, seeks to evaluate the combined effectiveness of the SERD camizestrant with the CDK4/6 inhibitor ribociclib for patients battling advanced HR+/HER2‑ breast cancer, who have seen limited responses to traditional treatments. This multi-city trial spans locations in Spain, Germany, and China.

About MEDSIR

Founded in 2012, MEDSIR has carved out a niche in the oncology sector through robust collaborations with strategic partners to promote innovative research. The company, operating from both Spain and the United States, offers comprehensive clinical trial management and is noted for its integrated technologies that streamline the research process. Through its strategic vision, MEDSIR engages in proof-of-concept studies and supports investigator-driven trials, ultimately amplifying the impact of cancer research on patient care. For more details, please visit www.medsir.org.